top of page

BackTable / Tumor Board / Podcast / Episode #27

Non-Muscle Invasive Bladder Cancer: Role of Medical Oncology

with Dr. Tyler Stewart

With the introduction of checkpoint inhibitors into non-muscle invasive bladder cancer (NMIBC) management, who’s on point for planning, administering, and optimizing combination therapies? Is it still the urologist, or does medical oncology play a more significant role now than it did before? In this episode of the BackTable 2025 NMIBC Creator Weekend™ series, host Dr. Bogdana Schmidt sits down with Dr. Tyler Stewart, medical oncologist from the University of California San Diego, to discuss the contemporary role of medical and surgical oncology in treating non-muscle invasive bladder cancer.

This podcast is supported by:

Be part of the conversation. Put your sponsored messaging on this episode. Learn how.

Non-Muscle Invasive Bladder Cancer: Role of Medical Oncology with Dr. Tyler Stewart on the BackTable Tumor Board Podcast
Ep 27 Non-Muscle Invasive Bladder Cancer: Role of Medical Oncology with Dr. Tyler Stewart
00:00 / 01:04

BackTable, LLC (Producer). (2025, October 7). Ep. 27 – Non-Muscle Invasive Bladder Cancer: Role of Medical Oncology [Audio podcast]. Retrieved from https://www.backtable.com

Stay Up To Date

Follow:

Subscribe:

Sign Up:

Podcast Contributors

Dr. Bogdana Schmidt on the BackTable Urology Podcast

Dr. Bogdana Schmidt, MD, MPH, is a urologic surgeon specializing in urologic oncology at the University of Utah in Salt Lake City, Utah.

Dr. Tyler Stewart on the BackTable Tumor Board Podcast

Dr. Tyler Stewart is a medical oncologist and associate professor at UC San Diego Health in California.

Synopsis

The conversation covers the efficacy and safety of checkpoint inhibitors like pembrolizumab, the importance of a multidisciplinary approach, and the challenges of balancing systemic and localized treatments. They also touch upon the potential future role of biomarkers in reducing invasive procedures and improving patient outcomes.

Timestamps

00:00 - Introduction
02:04 - The Role of Medical Oncologists in Bladder Cancer
12:58 - Combination Therapies and Patient Outcomes
21:18 - The CREST Study
26:59 - Managing Adverse Events
34:44 - Collaboration Between Urologists and Oncologists
41:06 - Conclusion and Final Thoughts

Resources

The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.

backtable-plus-vi-cta.jpg
Become a BackTable Sponsor

Up Next

HER2-Positive Metastatic Breast Cancer: Treatment Insights & Protocols with Dr. Erika Hamilton on the BackTable Tumor Board Podcast
NSCLC Treatment: Bispecific Antibodies & EGFR Mutations with Dr. Wade Iams on the BackTable Tumor Board Podcast
Pulse Electrical Field Ablation: Lung Cancer Applications & Benefits with Dr. William Moore and Dr. Daniel Sterman on the BackTable Tumor Board Podcast
Urothelial Carcinoma: Understanding ctDNA & Precision Medicine with Dr. Amanda Nizam and Dr. Brad McGregor on the BackTable Tumor Board Podcast
ESMO Update: Advances in Upper GI Malignancies with Dr. Jun Gong and Dr. Jonathan Mizrahi on the BackTable Tumor Board Podcast
Complex HCC Patients & The "Grey Zone": What To Do When You Don’t Know What To Do with Dr. Adam Burgoyne, Dr. Zach Berman, Dr. Kirema Garcia-Reyes and Dr. Lingling Du on the BackTable Tumor Board Podcast

Articles

Topics

Immune Checkpoint Inhibitors Podcasts
Immunotherapy Podcasts
Medical Oncology Podcasts
Oncology Podcasts

Get in touch!

We want to hear from you. Let us know if you’re interested in partnering with BackTable as a Podcast guest, a sponsor, or as a member of the BackTable Team.

bottom of page